Skip to main content
Top
Published in: Diabetologia 1/2006

01-01-2006 | Short Communication

Do HbA1c levels and the self-monitoring of blood glucose levels adequately reflect glycaemic control during pregnancy in women with type 1 diabetes mellitus?

Authors: A. Kerssen, H. W. de Valk, G. H. A. Visser

Published in: Diabetologia | Issue 1/2006

Login to get access

Abstract

Aims/hypothesis

Pregnancies of women with type 1 diabetes mellitus are associated with maternal and perinatal complications. These complication rates remain elevated despite achievement of the treatment goals described in the widely used guidelines of the American Diabetes Association (i.e. HbA1c level ≤7.0%). Against this background, we sought to answer two questions: (1) are HbA1c levels within 1% above normal appropriate in pregnant women with type 1 diabetes or should treatment be aimed at normal HbA1c levels; and (2) how many self-monitored blood glucose (SMBG) levels are needed per day to obtain an adequate image of glycaemic control in pregnant women with type 1 diabetes?

Materials and methods

We asked 43 pregnant women with type 1 diabetes to use the Continuous Glucose Monitoring System (CGMS) once in each trimester of pregnancy, while continuing their SMBG measurements. Glucose levels measured with the CGMS were compared between patients with HbA1c levels of 4.0–6.0%, 6.0–7.0% and >7.0%. Self-monitored glucose levels and those measured with CGMS were compared between patients with four or five, six to nine and ten or more SMBG determinations daily.

Results

In patients with HbA1c levels ≤6.0%, the glucose levels obtained by CGMS were significantly better than in patients with HbA1c levels >6.0%. In women with HbA1c levels 6.0–7.0% and >7.0%, these levels did not differ. The detection rate of hyper- and hypoglycaemic episodes was significantly higher in patients with ten or more SMBG determinations daily than in patients with fewer than ten.

Conclusions/interpretation

Treatment of diabetes in pregnant women should be aimed at achieving HbA1c levels within the normal range, i.e. ≤6.0%. A minimum of ten SMBG determinations daily is necessary to obtain adequate information of all daily glucose fluctuations.
Literature
1.
go back to reference Evers IM, de Valk HW, Visser GHA (2004) Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands. BMJ 328:915PubMedCrossRef Evers IM, de Valk HW, Visser GHA (2004) Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands. BMJ 328:915PubMedCrossRef
2.
go back to reference ADA (2004) Preconception care of women with diabetes. Diabetes Care 27[Suppl 1]:S76–S78 ADA (2004) Preconception care of women with diabetes. Diabetes Care 27[Suppl 1]:S76–S78
3.
go back to reference Suhonen L, Hiilesmaa V, Teramo K (2000) Glycaemic control during early pregnancy and fetal malformations in women with type I diabetes mellitus. Diabetologia 43:79–82PubMedCrossRef Suhonen L, Hiilesmaa V, Teramo K (2000) Glycaemic control during early pregnancy and fetal malformations in women with type I diabetes mellitus. Diabetologia 43:79–82PubMedCrossRef
4.
go back to reference Kerssen A, Evers IM, Valk de HW, Visser GHA (2003) Poor glucose control in women with type 1 diabetes mellitus and ‘safe’ hemoglobin A1c values in the first trimester of pregnancy. J Matern Fetal Neonat Med 13:309–313CrossRef Kerssen A, Evers IM, Valk de HW, Visser GHA (2003) Poor glucose control in women with type 1 diabetes mellitus and ‘safe’ hemoglobin A1c values in the first trimester of pregnancy. J Matern Fetal Neonat Med 13:309–313CrossRef
5.
go back to reference ADA (2004) Standards of medical care in diabetes. Diabetes Care 27(Suppl 1):S15–S35 ADA (2004) Standards of medical care in diabetes. Diabetes Care 27(Suppl 1):S15–S35
6.
go back to reference Mastrototaro J (1999) The MiniMed Continuous Glucose Monitoring System (CGMS). J Pediatr Endocrinol Metab 12(Suppl 3):751–758PubMed Mastrototaro J (1999) The MiniMed Continuous Glucose Monitoring System (CGMS). J Pediatr Endocrinol Metab 12(Suppl 3):751–758PubMed
7.
go back to reference Kerssen A, de Valk HW, Visser GHA (2004) The Continuous Glucose Monitoring System during pregnancy of women with type 1 diabetes mellitus; accuracy assessment. Diabetes Technol Ther 6:645–651PubMedCrossRef Kerssen A, de Valk HW, Visser GHA (2004) The Continuous Glucose Monitoring System during pregnancy of women with type 1 diabetes mellitus; accuracy assessment. Diabetes Technol Ther 6:645–651PubMedCrossRef
8.
go back to reference Rayburn W, Piehl E, Jacober S, Schork A, Ploughman L (1986) Severe hypoglycemia during pregnancy: its frequency and predisposing factors in diabetic women. Int J Gynaecol Obstet 24:263–268PubMedCrossRef Rayburn W, Piehl E, Jacober S, Schork A, Ploughman L (1986) Severe hypoglycemia during pregnancy: its frequency and predisposing factors in diabetic women. Int J Gynaecol Obstet 24:263–268PubMedCrossRef
9.
go back to reference Rosenn B, Siddiqi TA, Miodovnik M (1995) Normalization of blood glucose in insulin-dependent diabetic pregnancies and the risks of hypoglycemia: a therapeutic dilemma. Obstet Gynecol Surv 50:56–61PubMedCrossRef Rosenn B, Siddiqi TA, Miodovnik M (1995) Normalization of blood glucose in insulin-dependent diabetic pregnancies and the risks of hypoglycemia: a therapeutic dilemma. Obstet Gynecol Surv 50:56–61PubMedCrossRef
10.
go back to reference Kerssen A, de Valk HW, Visser GHA (2004) Day-to-day glucose variability during pregnancy in women with type 1 diabetes mellitus: glucose profiles measured with the Continuous Glucose Monitoring System. Br J Obstet Gynecol 111:919–924 Kerssen A, de Valk HW, Visser GHA (2004) Day-to-day glucose variability during pregnancy in women with type 1 diabetes mellitus: glucose profiles measured with the Continuous Glucose Monitoring System. Br J Obstet Gynecol 111:919–924
Metadata
Title
Do HbA1c levels and the self-monitoring of blood glucose levels adequately reflect glycaemic control during pregnancy in women with type 1 diabetes mellitus?
Authors
A. Kerssen
H. W. de Valk
G. H. A. Visser
Publication date
01-01-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 1/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-0057-7

Other articles of this Issue 1/2006

Diabetologia 1/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine